Document 1039 DOCN M94A1039 TI Effects of megestrol acetate therapy upon body composition and serum testosterone in AIDS. DT 9412 AU Engelson ES; Tierney AR; Pi-Sunyer FX; Kotler DP; St. Luke's-Roosevelt Hosp, NY, NY 10025. SO Int Conf AIDS. 1994 Aug 7-12;10(2):222 (abstract no. PB0900). Unique Identifier : AIDSLINE ICA10/94371536 AB OBJECTIVE: To evaluate the effects of megestrol acetate (MA) upon body composition and total serum testosterone (T). METHODS: We evaluated 11 AIDS patients receiving MA (100, 400, 800 mg/day) over 3 months, and compared results to 14 AIDS (C) undergoing longitudinal followup without therapy. Body cell mass (BCM) and fat content were determined by bioimpedance analysis (RJL101) in MA, while BCM was estimated by whole body counting of 40K and fat by anthropometric measurements in C. T was determined by radioimmunoassay. RESULTS: Baseline, weight, fat, BCM, and T were similar in MA and C. Over 12 weeks, MA gained an average of 4.7 kg of weight (p < 0.001 vs base), 0.4 kg BCM (NS), and 2.8 kg of fat, (p = 0.005) whereas C lost 0.7 kg of weight (NS), 0.8 kg BCM (NS), and gained an average of 1.2 kg fat (NS). Of the weight gained in MA, 81% consisted of fat while 19% consisted of BCM. During MA treatment, T fell significantly (p < 0.001). In contrast, T was stable in C. The changes in T were similar at all doses of MA. DISCUSSION AND CONCLUSIONS: MA increases body weight and decreases T. Fat accumulation in MA may be the result of a decreased anabolic effect mediated by the decrease in T. DE Acquired Immunodeficiency Syndrome/BLOOD/*DRUG THERAPY Body Composition/*DRUG EFFECTS Body Weight/DRUG EFFECTS Human Megestrol/*ANALOGS & DERIVATIVES/PHARMACOLOGY/THERAPEUTIC USE Testosterone/*BLOOD MEETING ABSTRACT SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).